Abstract:Background: Most randomized controlled trials with a time-to-event outcome are designed assuming proportional hazards (PH) of the treatment effect. The sample size calculation is based on a logrank test. However, non-proportional hazards are increasingly common. At analysis, the estimated hazards ratio with a confidence interval is usually presented. The estimate is often obtained from a Cox PH model with treatment as a covariate. If non-proportional hazards are present, the logrank and equivalent Cox tests may lose power. To safeguard power, we previously suggested a 'joint test' combining the Cox test with a test of non-proportional hazards. Unfortunately, a larger sample size is needed to preserve power under PH. Here, we describe a novel test that unites the Cox test with a permutation test based on restricted mean survival time. Methods: We propose a combined hypothesis test based on a permutation test of the difference in restricted mean survival time across time. The test involves the minimum of the Cox and permutation test P-values. We approximate its null distribution and correct it for correlation between the two P-values. Using extensive simulations, we assess the type 1 error and power of the combined test under several scenarios and compare with other tests. We investigate powering a trial using the combined test. Results: The type 1 error of the combined test is close to nominal. Power under proportional hazards is slightly lower than for the Cox test. Enhanced power is available when the treatment difference shows an 'early effect', an initial separation of survival curves which diminishes over time. The power is reduced under a 'late effect', when little or no difference in survival curves is seen for an initial period and then a late separation occurs. We propose a method of powering a trial using the combined test. The 'insurance premium' offered by the combined test to safeguard power under non-PH represents about a single-digit percentage increase in sample size. Conclusions: The combined test increases trial power under an early treatment effect and protects power under other scenarios. Use of restricted mean survival time facilitates testing and displaying a generalized treatment effect.

Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

Stratified modestly-weighted log-rank tests in settings with an anticipated delayed separation of survival curves

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

A Group Sequential Design and Sample Size Estimation for an Immunotherapy Trial with a Delayed Treatment Effect.

Adaptive Promising Zone Design for Cancer Immunotherapy with Heterogeneous Delayed Treatment Effect

A Simulation-free Group Sequential Design with Max-combo Tests in the Presence of Non-proportional Hazards

Optimality of testing procedures for survival data

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

Quantifying treatment differences in confirmatory trials under non-proportional hazards

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

Group Sequential Design with Maximin Efficiency Robust Test for Immunotherapy with Generalized Delayed Treatment Effect.

The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

A two-step approach for analyzing time to event data under non-proportional hazards

Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting

A Utility-Based Design for Randomized Comparative Trials with Ordinal Outcomes and Prognostic Subgroups

Designing therapeutic cancer vaccine trials with delayed treatment effect

Design and Analysis of Clinical Trials in the Presence of Delayed Treatment Effect

Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials